The ColoCare Study (NCT02328677) is a prospective cohort of men and women diagnosed with primary invasive colorectal cancer (stages I-IV), with primary outcomes including quality-of-life, recurrence, and death.
It is the only colorectal cancer cohort that includes the collection of clinical and risk factor data and the sampling of a diverse panel of biospecimens at multiple critical time points (prior to surgery and at 3, 6, 12, 24, 36, 48, and 60 months post-surgery).
This unique design with repeat assessments enables innovative research into the:
- influence of lifestyle/behavioral factors on patient outcomes;
- ethnic/racial disparities in clinical outcomes;
- the discovery and validation of novel biomarkers from blood, urine and stool useful for guiding treatment decision-making and risk prediction; and
- interactions between treatment, risk factors, and biomarkers on clinical outcomes.
Dr. Ulrich initiated ColoCare together with Dr. Bill Grady at the Fred Hutchinson Cancer Research Center with subsequent consortium sites at the Moffitt Cancer Center, German Cancer Research Center, and Huntsman Cancer Institute (HCI).
ColoCare has successfully launched research on biologic determinants of:
- colorectal cancer (e.g., tumor immunity, gut microbiome, epigenome);
- health behaviors (e.g., physical activity, adipose tissue distribution);
- clinical endpoints (e.g., surgical complications); as well as
- interrelations between these factors in the context of colorectal cancer prognosis.
ColoCare Consortium Members
Other ColoCare Consortium members include currently:
- Fred Hutchinson Cancer Research Center
- Moffitt Cancer Center
- ColoCare Consortium
- University of Heidelberg in Germany
- Cedars Mt. Sinai
- Washington University School of Medicine in St. Louis
- University of Tennessee in Memphis
In addition, ColoCare has an affiliate member at the University of Heidelberg Department of Surgery (Prof. Dr. Alexis Ulrich) and participates in several international consortia.